Chronic antihypertensive treatment often includes combination of two or more therapies with complementary mechanism of action targeting different blood pressure (BP) control system. If available, these components are recommended to be administered as a fixed-dose combination (FDC) to reduce tablet burden, improve adherence and thus BP control. A combination of ramipril (RAMI) and bisoprolol (BISO) is one of the options used in clinical practice and is supported by therapeutic guidelines. The clinical program for a novel BISO/RAMI FDC consisted of two randomized, open-label, bioequivalence (BE) studies and one drug-drug interaction (DDI) study. The BE was examined between two FDC strengths of BISO/RAMI (10/10 and 10/5 mg) and the individual reference products administered concomitantly at respective doses after a single oral dose under fasting conditions. In both BE studies, 64 healthy subjects were randomized according to a two-way crossover design. The DDI study evaluated a potential pharmacokinetic (PK) interaction between BISO 10 mg and RAMI 10 mg following their single or concomitant administrations in 30 healthy subjects under fasting condition. BE for BISO/RAMI 10/5 mg and absence of a clinically relevant PK DDI between BISO and RAMI was demonstrated as the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) for area under the concentration time curve (AUC) and maximum concentration (Cmax ) remained within the acceptance range of 80.00 to 125.00%. However, BE for BISO/RAMI 10/10 mg was not demonstrated, as the lower bound of the 90% CI of Cmax for RAMI was outside the acceptance range of BE. Both drugs administered alone or combined were well-tolerated. No PK interaction was observed between BISO and RAMI/ramiprilat, since the co-administration of BISO and RAMI 10 mg single doses resulted in comparable rate and extent of absorption for BISO and RAMI when compared to their individual products.

Altasciences Laval Quebec Canada

Zentiva k s Prague Czech Republic

Zobrazit více v PubMed

Unger T, Borghi C, Charchar F, et al. 2020 international society of hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334‐1357. PubMed

Murray CJL, Aravkin AY, Zheng P, et al. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223‐1249. PubMed PMC

Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population‐based studies from 90 countries. Circulation. 2016;134:441‐450. PubMed PMC

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71:e127‐e248. PubMed

Williams B, Manica G, Soiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021‐3104. PubMed

Salam A, Kanukula R, Atkins E, et al. Efficacy and safety of dual combination therapy of blood pressure‐lowering drugs as initial treatment for hypertension: a systematic review and meta‐analysis of randomized controlled trials. J Hypertens. 2019;37:1768–1774. PubMed

Mallat SG, Tanios BY, Itani HS, Lotfi T, Akl EA. Free versus fixed combination antihypertensive therapy for essential arterial hypertension: a systematic review and meta‐analysis. PLoS One. 2016;11:e0161285. PubMed PMC

Richards TR, Tobe SW. Combining other antihypertensive drugs with β‐blockers in hypertension: a focus on safety and tolerability. Β‐Adren Recept Blockers Hypertens. 2014;30:S42‐S46. PubMed

Weber MA, Basile J, Stapff M, Khan B, Zhou D. Blood pressure effects of combined β‐blocker and angiotensin‐converting enzyme inhibitor therapy compared with the individual agents: a placebo‐controlled study with nebivolol and lisinopril. J Clin Hypertens. 2012;14:588‐592. PubMed PMC

Fendrikova A, Skibitsky V. PP.21.14: effectiveness of fixed‐dose combination of bisoprolol and amlodipine in patients with arterial hypertension and coronary heart disease. J Hypertens. 2015;33:e322.

Huttunen M, Lampainen E, Lilja M, et al. Which anti‐hypertensive to add to a beta‐blocker: ACE inhibitor or diuretic? J Hum Hypertens. 1992;6:121‐125. PubMed

Bursztyn M, Gavras I, Gourley L, et al. Effect of combination therapy with atenolol and the angiotensin‐converting enzyme inhibitor benazepril. Clin Ther. 1994;16:429‐436. PubMed

Wright JT Jr, Bakris GL, Bell DS, et al. Lowering blood pressure with β‐blockers in combination with other renin‐angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI trial. J Clin Hypertens. 2007;9:842‐849. PubMed PMC

Neutel JM, Smith DHG, Gradman AH. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I‐II hypertension. J Hum Hypertens. 2010;24:64‐73. PubMed

Belz GG, Breithaupt K, Erb K, Kleinbloesem CH, Wolf GK. Influence of the angiotensin converting enzyme inhibitor cilazapril, the beta‐blocker propranolol and their combination on haemodynamics in hypertension. J Hypertens. 1989;7:817‐824. PubMed

Bisognano JD, McLaughlin T, Roberts CS, Tang SSK. Calcium channel blockers, angiotensin receptor blockers, and angiotensin‐converting enzyme inhibitors: effectiveness in combination with diuretics or beta‐blockers for treating hypertension. Vasc Health Risk Manag. 2007;3:579‐585. PubMed PMC

Madej A, Buldak L, Basiak M, Szkrobka W, Dulawa A, Okopien B. The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. Int J Clin Pharmacol Ther. 2009;47:686‐694. PubMed

Elkohen M, Clerson P, Mounier‐Vehier C, Gressin V, Humbert R, Carre A. Effects of bisoprolol and ramipril on short‐term variability of systolic blood pressure during mental stress test: spectrum analysis. Arch Mal Coeur Vaiss. 1995;88:1075‐1080. PubMed

Brugts JJ, Bertrand M, Remme W, et al. The treatment effect of an ACE‐inhibitor based regimen with perindopril in relation to beta‐blocker use in 29,463 patients with vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS trials. Cardiovasc Drugs Ther. 2017;31:391‐400. PubMed PMC

Thoenes M, Neuberger H‐R, Volpe M, Khan BV, Kirch W, Bohm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens. 2010;24:336‐344. PubMed

Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129‐2200. PubMed

Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed‐dose combinations of antihypertensive agents. Hypertension. 2010;55:399‐407. PubMed

Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed‐dose combination antihypertensive medications, adherence, and clinical outcomes: a population‐based retrospective cohort study. PLoS Med. 2018;15:e1002584. PubMed PMC

Baser O, Andrews LM, Wang L, Xie L. Comparison of real‐world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single‐pill combination versus angiotensin receptor blocker/calcium channel blocker free‐combination therapy. J Med Econ. 2011;14:576‐583. PubMed

European Medicines Agency guideline on the investigation of bioequivalence. 2010. PubMed

Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S16‐S20. PubMed

Meisel S, Shamiss A, Rosenthal T. Clinical pharmacokinetics of ramipril. Clin Pharmacokinet. 1994;26:7‐15. PubMed

Merck Cardicor 10 mg film coated tablets summary of product characteristics. (2020).

Sanofi Tritace 10 mg tablets summary of product characteristics. (2019).

Merck Concor 5 mg and 10 mg film‐coated tablet summary of product characteristics. (2020).

Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure. Circ Res. 2013;113:739‐753. PubMed PMC

Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed‐dose combinations improve medication compliance: a meta‐analysis. Am J Med. 2007;120:713‐719. PubMed

Zisaki A, Miskovic L, Hatzimanikatis V. Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr Pharm Des. 2015;21:806‐822. PubMed PMC

Tamargo J, Rosano G, Walther T, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J ‐ Cardiovasc Pharmacother. 2017;3:163‐182. PubMed